Bladder Cancer
@BladderCaJrnl
BLC Journal | Dedicated to expediting our understanding & improving treatments of bladder and upper urinary tract cancers | Editors Seth Lerner, Dan Theodorescu
Stay updated with the latest content from our #BladderCancer journal by signing up to get news direct to your inbox. Go to: tiny.cc/BLCsignup Keep informed about new articles, challenging cases, reviews, & other features like our Clinical Trials Corner! #GoldOpenAccess
RESEARCH REPORT: BCG therapy for bladder cancer: Exploring patient experiences and concerns through artificial intelligence-based social media analysis by Zine-Eddine KHENE et al. journals.sagepub.com/doi/10.1177/23… @FaltasLab @Dan_Theodorescu @slernerbcmedu1
SHORT COMMUNICATION: Achieving health equity in bladder cancer care: Addressing disparities through collaborative research and evidence-based strategies by Yelba Castellon-Lopez and Patricia Thompson. journals.sagepub.com/doi/full/10.11… @FaltasLab @Dan_Theodorescu @slernerbcmedu1
The First Systematic Review and Meta-Analysis of Antiangiogenic Therapy Combined with Immune Checkpoint Inhibitors in Urothelial Cancer: Efficacy, Clinical Use and Future Applications by @mjmoussa_ et al. journals.sagepub.com/doi/full/10.11… @FaltasLab @Dan_Theodorescu @slernerbcmedu1
REVIEW: Systemic induction therapy in patients with locally advanced or node-positive urothelial carcinoma: evaluating treatment outcomes by Vera Rutten et al. journals.sagepub.com/doi/10.1177/23… @FaltasLab @Dan_Theodorescu @slernerbcmedu1
⚡️ On @EUplatinum - Intravesical durvalumab (1000 mg every 6 weeks) shows promise for high-risk NMIBC after BCG failure. - Feasible administration with negligible toxicity. - Encouraging efficacy as a localized immune checkpoint inhibitor. - Intravesical delivery may surpass…
🔥NOW in @BladderCaJrnl of @BladderCancerUS👉Can Combining ICIs w/ Antiangiogenic Agents Revive Antiangiogenic Therapy in Advanced Urothelial Cancer? @OAlhalabiMD @MDAndersonNews 1st Meta-Analysis: ORR 34% in ICI-naïve group vs 16% in ICI-exposed. Better patient selection🔑?
hot-off-press📝antiangiogenics+immune checkpoint blockade in urothelial cancer: Sys rev and meta-analysis @mjmoussa_, @kovalenkojuls, @emanuele_crupi, E Proskuriakova, Y. Geng, @GFallara_MD, R. Benkhadra, @DanieleRaggi83, @DocMattCampbell @PavlosMsaouel journals.sagepub.com/doi/10.1177/23…
RESEARCH REPORT: North American Study and Meta-analysis Evaluating Performance of Bladder EpiCheck®, a FDA cleared test, in Non-Muscle Invasive Bladder Cancer Recurrence by Neil Fleshner et al. journals.sagepub.com/doi/full/10.11… @FaltasLab @Dan_Theodorescu @slernerbcmedu1
Research Report: Repeat TURBT in large volume HG Ta NMIBC treated with induction BCG therapy was not associated with improved high-risk recurrence-free survival. @durant_adri et al. journals.sagepub.com/doi/full/10.11…. @FaltasLab @Dan_Theodorescu @slernerbcmedu1
RESEARCH REPORT: Effectiveness of prolonged antibiotic prophylaxis in radical cystectomy: preliminary analysis of the MACS randomized clinical trial by Mariya Berkut et al. pmc.ncbi.nlm.nih.gov/articles/PMC11…. @FaltasLab @Dan_Theodorescu @slernerbcmedu1
SHORT COMMUNICATION: Lifestyle Advice to Patients with Bladder Cancer: A National Survey of Dutch Urologists by Ivy Beeren et al. pmc.ncbi.nlm.nih.gov/articles/PMC11… @FaltasLab @Dan_Theodorescu @slernerbcmedu1
POSITION PAPER: Eligibility and endpoints for clinical trials in trimodality therapy for bladder cancer by @RonaldChenMD, @slernerbcmedu1, @sonpavde, @HimanshuNagarMD, @Parminder1699 et al. pmc.ncbi.nlm.nih.gov/articles/PMC11… @FaltasLab @Dan_Theodorescu
NEW REVIEW focusing on ctDNA👉Perioperative use of ctDNA to Guide Treatment for Urothelial Carcinoma: The Future is Now👈by @DrTylerStewart et al. pmc.ncbi.nlm.nih.gov/articles/PMC11… @DrChoueiri @FaltasLab @slernerbcmedu1
New Research Report: A molecular urine assay to detect recurrences during surveillance of high-risk non-muscle invasive bladder cancer by @FCdeJong, @JoepJdeJong, et al. pmc.ncbi.nlm.nih.gov/articles/PMC11… @FaltasLab @Dan_Theodorescu @slernerbcmedu1
Happy to present the latest review in Bladder Cancer by @SandeepGurramMD and @RathiNityam from @NCICCR_UroOnc "Device-Assisted Therapy in Non-Muscle-Invasive Bladder Cancer" discussing ✅Rationale for devices ✅Devices available ✅Mechanisms ✅Efficacy ✅Safety ✅Future Studies
⚡️ Bladder Adjuvant Radiation Therapy (BART): Acute and Late Toxicity From a Phase III Multicenter Randomized Controlled Trial #BladderCancer @docpriyamvada @VedangMurthy sciencedirect.com/science/articl…
In @Nature: Full text article "Leveraging programmed cell death signature to predict clinical outcome and immunotherapy benefits in postoperative bladder cancer." Click here to read it: nature.com/articles/s4159…
The interplay of mutagenesis and ecDNA shapes urothelial cancer evolution. 👇
🚀Big News! Excited to share our work “The Interplay of Mutagenesis and ecDNA Shapes Urothelial Cancer Evolution” published in @Nature! nature.com/articles/s4158…
⚡️ On @EUplatinum - Whole-genome Mutational Analysis for Tumor-informed Detection of Circulating Tumor DNA in Patients with Urothelial Carcinoma #BladderCancer @IverNordentoft @SiaLindskrog europeanurology.com/article/S0302-…
⚡️ Durable Objective Response to Lurbinectedin in Small Cell Bladder Cancer with TP53 Mutation: A Molecular-Directed Strategy #BladderCancer @mjmoussa_ @OAlhalabiMD @PavlosMsaouel @DocMattCampbell mdpi.com/1718-7729/31/6…
Pre-BCG peri-tumoral TLSs, from our study, on the cover of October, 2025 issue!!! Beautiful artwork (a storm exhausting the immune cell cluster in BCG unresponsive NMIBC tumors) by Lewis Long. Thank you @CIR_AACR !!! aacrjournals.org/cancerimmunolr…